Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Breakthrough Profiling Technology to Improve Cancer Treatment on a Personalized Basis

Published: Saturday, April 12, 2014
Last Updated: Saturday, April 12, 2014
Bookmark and Share
New research paper published in the peer reviewed journal PLOS ONE.

The possibility of patients with pancreatic cancer being able to have their cancer tissue ‘profiled’ to understand how they will react to different treatments before they are given to them has moved a lot closer, a new research paper shows, published in the peer reviewed journal PLOS ONE.

This will enable more accurate profiling and the best drug selection for each individual. Trials are being planned to undertake the final stage of the process.

A recent study by UK Biosciences company, Proteome Sciences plc, in collaboration with leading academic partners King’s College Hospital, Imperial College London and the University of Cardiff, has shown this new method of analysis, using a system known as ‘SysQuant’ developed by Proteome Sciences, can unravel the chain of complex molecular activity that leads to and propagates cancer and be used to accurately predict how specific drug treatments will affect different patients with pancreatic cancer.

This new technique, which does not increase the overall cost of treatment, will provide doctors with information that will allow them to select which therapy will best work on an individual patient using existing medicines, something which to date has not been possible to achieve in most types of cancer. The researchers hope this will soon be applied across all cancers.

In the study, tumour, or cancerous tissue from 12 pancreatic cancer patients was analyzed involving over 2,100 proteins and 6,284 unique phosphorylation sites (which are common in modulating the activity of cancer suppressing proteins) being surveyed in each sample.

Commenting on this study, Professor Nigel Heaton, Professor of ‎Professor of Liver Transplant, Hepatobiliary and Pancreatic Surgery at King’s College Hospital said: “Cancer is caused by a chain reaction of many different chemicals in the body. Treatment looks to disrupt that chain reaction but how we do this can vary hugely from one person to the next.

“Understanding the chemical make-up of an individual patient will help us understand which patients will respond to treatment. At the moment, only 20% of patients will respond to standard treatment for pancreatic cancer so this new technology will help us predict beforehand which patients are most likely to respond and which will not.

“If we know what treatments will be the most effective before we administer them this gives us a huge advantage to help patients as well as save the NHS money by eliminating spending on treatments that won’t work.

Heaton continued, “It is a hugely promising step forward, not just for patients with pancreatic cancer, but for all people with cancer.”

Dr. Debashis Sarker, Senior Lecturer and Consultant in Medical Oncology at Kings College Hospital, London added: “The PLOS ONE paper shows the critical cancer proteins and pathways that are deregulated for each patient in pancreatic cancer using SysQuant. These differ from patient to patient indicating the need for a personalized approach to each patient’s treatments. Clinical trials should now be designed to compare standard therapy approaches compared to matching aberrant protein pathways with specific targeted therapies.”

Professor Justin Stebbing, Professor of Cancer Medicine and Medical Oncology, Consultant Oncologist, Imperial College London and Imperial College Healthcare NHS Trust said: "This work demonstrates the network of interactions, the fingerprint and signature of phosphorylation events in cancer. It provides an opportunity to study some of the major tumorigenic events in a test tube using the very latest in mass spectrometry-based technologies. This is the way forwards in cell signalling".

Referring to the study, Dr. Ian Pike, Chief Operating Officer at Proteome Sciences, commented: “This study is the first peer-reviewed article using the SysQuant® technology, which in this case identified the common and unique molecular events involved in pancreatic cancer. The results clearly demonstrate the potential to significantly improve the way bespoke treatments can be matched to each individual patient, prior to the administration of any drugs, using already approved medicines.

Dr. Pike continued, “This technology can also be used for the analysis of tissues across a range of different diseases including all other cancers. Furthermore it can be utilized to assess drugs which are in pre-clinical development much more efficiently and cost effectively than is currently possible.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Proteome Sciences to Develop Cancer Pathway Profiling Assays
New MS3 TMT® mass spectrometry technique to determine relative quantitation of proteins in multiple samples simultaneously.
Monday, June 17, 2013
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
TOPLESS Plants Provide Clues to Human Molecular Interactions
Scientists at Van Andel Research Institute have revealed an important molecular mechanism in plants that has significant similarities to certain signaling mechanisms in humans, which are closely linked to early embryonic development and to diseases such as cancer.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!